Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint.

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
M W KonstanDonald R VanDevanter

Abstract

Rate of lung function decline (RLFD) (as FEV(1) percent predicted/yr) is a robust measure of CF therapeutic efficacy rarely used as a study endpoint, in part due to uncertainty of sample size requirements. Sample size requirements for 1:1 randomizations to detect RLFD treatment effects from 20% to 80% were assessed in Epidemiologic Study of CF (ESCF) patients. Effects of measuring FEV(1) 1-4 times per year in studies of 1- to 4-year durations were assessed in 399 patients age ≥ 6 years with FEV(1) ≥ 70%. Impacts of inclusion/exclusion based on risk factors in 2369 ESCF patients were assessed over 1.5 years using semi-annual FEV(1) measures. Increasing study duration and exclusion of lower risk patients (e.g., no P. aeruginosa infection) both substantially reduced requirements. CF RLFD studies of 1.5 years in duration appear feasible provided that investigators account for the beneficial effects of subject inclusion/exclusion based on risk factors in power estimates.

References

Mar 30, 1995·The New England Journal of Medicine·M W KonstanP B Davis
Jan 15, 1998·The Journal of Pediatrics·M CoreyM Knowles
Jan 5, 1999·American Journal of Respiratory and Critical Care Medicine·J L HankinsonK B Fedan
Oct 2, 2003·JAMA : the Journal of the American Medical Association·Lisa SaimanUNKNOWN Macrolide Study Group
Jan 20, 2006·The New England Journal of Medicine·Mark R ElkinsUNKNOWN National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group
Jul 24, 2007·The Journal of Pediatrics·Michael W KonstanUNKNOWN Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis
Aug 28, 2007·The Journal of Pediatrics·Larry C LandsMary Corey

❮ Previous
Next ❯

Citations

Jun 23, 2011·American Journal of Respiratory and Critical Care Medicine·Peter J Mogayzel, Patrick A Flume
Sep 17, 2013·Drug Design, Development and Therapy·Ruth O'Reilly, Heather E Elphick
Jul 2, 2015·American Journal of Respiratory and Critical Care Medicine·Gregory S SawickiMichael W Konstan
Jul 7, 2015·Annals of the American Thoracic Society·Theodore J TorphyUNKNOWN Antiinflammatory Therapy Working Group
May 9, 2012·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Michael W KonstanWayne J Morgan
Sep 18, 2014·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·C ConradR Tirouvanziam
Aug 14, 2012·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Donatello SalvatoreGianni Mastella
Jan 21, 2016·Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia·João Paulo Heinzmann-FilhoMárcio Vinícius Fagundes Donadio
Jan 15, 2017·The Journal of Pediatrics·Márcio V F DonadioPaulo J C Marostica
Dec 25, 2016·The Lancet. Respiratory Medicine·Steven M Rowe
Jul 8, 2011·Journal of the Royal Society of Medicine·Mandy Bryon, Colin Wallis
Jan 10, 2018·Annals of the American Thoracic Society·Michael W KonstanWayne J Morgan
Dec 11, 2013·Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine·John LamMichael D Parkins
Feb 8, 2018·Revista paulista de pediatria : orgão oficial da Sociedade de Pediatria de São Paulo·Daniela Barbieri HauschildYara Maria Franco Moreno
Oct 4, 2019·The Cochrane Database of Systematic Reviews·Oana CiofuJens Lykkesfeldt
Jul 5, 2012·Annals of the New York Academy of Sciences·Jason P EiserichCarroll E Cross
Oct 3, 2012·Current Opinion in Pulmonary Medicine·Janet StocksSamatha Sonnappa
Jan 1, 2012·Clinical Investigation·Donald R VanDevanter, Michael W Konstan
Jun 19, 2015·Pediatric Pulmonology·Margaret RosenfeldUNKNOWN Investigators of Coordinators of the Epidemiologic Study of Cystic Fibrosis
Jun 16, 2017·American Journal of Respiratory and Critical Care Medicine·Gregory S SawickiJeffrey S Wagener
Dec 6, 2019·Therapeutic Advances in Chronic Disease·Paula Rodriguez-MiguelezRyan A Harris
Jan 13, 2021·Pediatric Pulmonology·Michael W KonstanUNKNOWN Scientific Advisory Group and the Investigators and Coordinators of ESCF
Jun 23, 2020·Paediatric Respiratory Reviews·I M Balfour-Lynn, J A King

❮ Previous
Next ❯

Related Concepts

Related Feeds

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Related Papers

Pediatric Pulmonology
M W KonstanScientific Advisory Group and Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis
The Journal of Pediatrics
M W KonstanScientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis
The Journal of Pediatrics
Clement L RenScientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis
The New England Journal of Medicine
M W KonstanPamela B Davis
American Journal of Respiratory and Critical Care Medicine
Patrick A FlumeCystic Fibrosis Foundation, Pulmonary Therapies Committee
© 2021 Meta ULC. All rights reserved